Zacks Investment Research downgraded Veracyte Inc (NASDAQ:VCYT) to Sell in a report released today.
- Updated: October 6, 2016
Zacks Investment Research has downgraded Veracyte Inc (NASDAQ:VCYT) to Sell in a report released on 10/06/2016.
Previously on 10/14/2015, Cowen reported about Veracyte Inc (NASDAQ:VCYT) lowered the target price from $12.00 to $8.00. At the time, this indicated a possible upside of 0.37%.
Yesterday Veracyte Inc (NASDAQ:VCYT) traded -0.77% lower at $7.66. The company’s 50-day moving average is $6.40 and its 200-day moving average is $5.53. The last stock close price is up 39.37% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 3,625 shares of the stock were exchanged, down from an average trading volume of 58,349
See Chart Below
Veracyte Inc has a 52 week low of $4.21 and a 52 week high of $8.15 The company’s market cap is currently $0.
About Veracyte Inc (NASDAQ:VCYT)
Veracyte, Inc. is a molecular diagnostics company. The Company is engaged in developing and delivering genomic solutions that resolve diagnostic ambiguity and enable physicians to make informed treatment decisions at an early-stage in patient care. The Company targets diseases in which various patients undergo diagnostic procedures that could be avoided with diagnosis from a cytology sample taken preoperatively. It operates in the United States. The Company's commercial solution, the Afirma Thyroid fine needle aspiration (FNA) Analysis is its offering for thyroid nodule assessment. The solution centers on its Afirma Gene Expression Classifier to resolve indeterminate FNA results, based on cytopathology, so that patients whose nodules are benign can avoid unnecessary diagnostic surgery and undergo routine monitoring instead. The Company's pulmonology product is designed to identify idiopathic pulmonary fibrosis, among patients presenting with a suspected interstitial lung disease.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.